source
- Oak Hill Bio merges with RA Capital SPAC; InnoCare's TYK2 drug hits in Phase 3💵 Oak Hill Bio’s SPAC merger: The Angelman syndrome biotech will merge with RA Capital’s blank-check company, called Research Alliance Corporation III, and get about ...
- Alnylam's stock is down 30% despite a booming biotech market. Here's whyAlnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A is up, IPOs are back with record-breaking force a…